Advertisement

Breast Disease pp 209-219 | Cite as

Breast-Conserving Therapy: Hypofractionated and Conventional Whole-Breast Irradiation and Accelerated Partial-Breast Irradiation

  • Fusun Tokatlı
  • Maktav DincerEmail author
Chapter

Abstract

Breast irradiation after breast-conserving surgery (BCS) is an essential component of breast conservation therapy for maximizing local control and overall survival. The most widely used fractionation regimen until recently was 1.8- to 2-Gy daily fractions for a total of 45–50 Gy to the whole breast over 5 weeks with or without a boost to the surgical bed. However, a new optimal dose and fractionation schedule for radiation therapy after BCS has been defined recently. There is renewed interest in hypofractionation for whole-breast irradiation (WBI), and this approach has important practical advantages and biological implications. The convenience of this method may facilitate patient acceptance and compliance with radiation therapy. Irradiating only the tumor-bearing quadrant of the breast in one to ten fractions instead of irradiating the whole breast after BCS has also increased in popularity recently.

Keywords

Irradiation Partial breast Breast conservation Accelerated radiotherapy Radiotherapy complications Cosmesis Boost dose Randomized trials Breast conserving Canadian trial Cosmetic outcome Fraction size Hypofractionation Normal tissue Local control Meta-analyses START-A START-B UK FAST Survival Whole breast α/β ratio 

References

  1. 1.
    Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effects of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10801 women in 17 randomized trials. Lancet. 2011;378:1707–16.CrossRefGoogle Scholar
  2. 2.
    Fisher B, Anderson S, Bryant J, Margolese RG, Deutsch M, Fisher ER, et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med. 2002;347:1233–41.CrossRefGoogle Scholar
  3. 3.
    Veronesi U, Luini A, Del Vecchio M, Greco M, Galimberti V, Merson M, et al. Radiotherapy after breast-preserving surgery in women with localized cancer of the breast. N Engl J Med. 1993;328:1587–91.CrossRefGoogle Scholar
  4. 4.
    Theberge V, Whelan T, Shatelman SF, Vicini F. Altered fractionation: rationale and justification for whole and partial breast hypofractionated radiotherapy. Semin Radiat Oncol. 2011;21:55–65.CrossRefGoogle Scholar
  5. 5.
    Hall EJ, Giaccia AJ. Radiobiology for the radiologists. Philadelphia: Lippincott Williams & Wilkins; 2006.Google Scholar
  6. 6.
    Thames HD, Bentzen SM, Turesson I, Overgaard M, Van den Bogaert W. Time-dose factors in radiotherapy: a review of the human data. Radiother Oncol. 1990;19:219–35.CrossRefGoogle Scholar
  7. 7.
    Williams MV, Denekemp J, Fowler JF. A review of α/β ratios for experimental tumors: implications for clinical studies of altered fractionation. Int J Radiat Oncol Biol Phys. 1985;11:87–96.CrossRefGoogle Scholar
  8. 8.
    Yarnold J, Ashton A, Bliss J, Homewood J, Harper C, Hanson J, et al. Fractionation sensitivity and dose response of late adverse effects in the breast after radiotherapy for early breast cancer: long-term results of a randomized trial. Radiother Oncol. 2005;75:9–17.CrossRefGoogle Scholar
  9. 9.
    Owen JR, Ashton A, Bliss JM, Homewood J, Harper C, Hanson J, et al. Effect of radiotherapy fraction size on tumor control in patients with early-stage breast cancer after local tumor excision: long-term results of a randomized trial. Lancet Oncol. 2006;7:467–71.CrossRefGoogle Scholar
  10. 10.
    Whelan T, MacKenzie R, Julian J, Levine M, Shelley W, Grimard L, et al. Randomized trial of breast irradiation schedules after lumpectomy for women with lymph node-negative breast cancer. J Natl Cancer Inst. 2002;94:1143–50.CrossRefGoogle Scholar
  11. 11.
    Whelan T, Pignol J, Levine M, Julian J, Mackenzie R, Parpia S, et al. Long-term results of hypofractionated radiation therapy for breast cancer. N Engl J Med. 2010;362:513–20.CrossRefGoogle Scholar
  12. 12.
    Cox JD, Stetz J, Pajak TF. Toxicity criteria of the radiation therapy oncology group (RTOG) and the European organization for research and treatment of cancer (EORTC). Int J Radiat Oncol Biol Phys. 1995;31:1341–6.CrossRefGoogle Scholar
  13. 13.
    The START Trialists’ Group. The UK Standardization of Breast Radiotherapy (START) Trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomized trial. Lancet Oncol. 2008;9:331–41.CrossRefGoogle Scholar
  14. 14.
    Haviland JS, Owen JR, Dewar JA, Agrawal RK, Barrett-Lee PJ, Dobbs HJ, et al. The UK Standardization of Breast Radiotherapy (START) Trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomized controlled trials. Lancet Oncol. 2013;14:1086–94.CrossRefGoogle Scholar
  15. 15.
    The START Trialists’ Group. The UK Standardization of Breast Radiotherapy (START) Trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomized trial. Lancet. 2008;371:1098–107.CrossRefGoogle Scholar
  16. 16.
    The FAST Trialists Group. First results of the randomized UK FAST trial of radiotherapy hypofractionation for treatment of early breast cancer (CRUKE/04/015). Radiother Oncol. 2011;100:93–100.CrossRefGoogle Scholar
  17. 17.
    Jones B, Dale RG, Deehan C, Hopkins KI, Morgan DA. The role of biologically effective dose (BED) in clinical oncology. Clin Oncol. 2001;13:71–81.Google Scholar
  18. 18.
    Williamson D, Dinniwell R, Fung S, Pintilie M, Done SJ, Fyles AW. Local control with conventional and hypofractionated adjuvant radiotherapy after breast-conserving surgery for ductal carcinoma in-situ. Radiother Oncol. 2010;95:317–20.CrossRefGoogle Scholar
  19. 19.
    Moody AM, Mayles WP, Bliss JM, A’Hern RP, Owen JR, Regan J, et al. The influence of breast size on late radiation effects and association with radiotherapy dose inhomogeneity. Radiother Oncol. 1994;33:106–12.CrossRefGoogle Scholar
  20. 20.
    Olivotto IA, Weir LM, Kim-Sing C, Bajdik CD, Trevisan CH, Doll CM, et al. Late cosmetic results of short fractionation for breast conservation. Radiother Oncol. 1996;41:7–13.CrossRefGoogle Scholar
  21. 21.
    Galecki F, Hicer-Grzenkowicz J, Grudzien-Kowalska M, Michalska T, Załucki W. Radiation-induced brachial plexopathy and hypofractionated regimens in adjuvant irradiation of patients with breast cancer-a review. Acta Oncol. 2006;45:280–4.CrossRefGoogle Scholar
  22. 22.
    Johansson S, Svensson H, Denekamp J. Timescale of evolution of late radiation injury after postoperative radiotherapy of breast cancer patients. Int J Radiat Oncol Biol Phys. 2000;48:745–50.CrossRefGoogle Scholar
  23. 23.
    Olsen NK, Pfeiffer P, Johannsen L, Schrøder H, Rose C. Radiation-induced brachial plexopathy: neurological follow-up in 161 recurrence-free breast cancer patients. Int J Radiat Oncol Biol Phys. 1993;26:43–9.CrossRefGoogle Scholar
  24. 24.
    Schultheiss TE. The radiation dose-response of the human spinal cord. Int J Radiat Oncol Biol Phys. 2008;71:1455–9.CrossRefGoogle Scholar
  25. 25.
    Haviland JS, Mannino M, Griffin C, Porta N, Sydenham M, Bliss JM, Yarnold JR, on behalf of the START Trialists’ Group. Late normal tissue effects in the arm and shoulder following lymphatic radiotherapy: results from the UK START (Standardisation of Breast Radiotherapy) trials. Radiother Oncol. 2018;126:155–162.Google Scholar
  26. 26.
    Bartelink H, Arriagada R. Hypofractionation in radiotherapy for breast cancer. Lancet. 2008;371:1050–2.CrossRefGoogle Scholar
  27. 27.
    Taylor CW, McGale P, Darby SC. Cardiac risks of breast-cancer radiotherapy: a contemporary view. Clin Oncol (R Coll Radiol). 2006;18:236–46.CrossRefGoogle Scholar
  28. 28.
    Darby SC, Ewertz M, McGale P, Bennet AM, Blom-Goldman U, Brønnum D, et al. Risk of ischemic heart disease in women after radiotherapy for breast cancer. N Engl J Med. 2013;368:987–98.CrossRefGoogle Scholar
  29. 29.
    Clarke M, Collins R, Darby S, Davies C, Elphinstone P, Evans E, Early Breast Cancer Trialists’ Collaborative Group (EBCTCG), et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomized trials. Lancet. 2005;366:2087–106.CrossRefGoogle Scholar
  30. 30.
    Journal Club. Are three weeks of whole-breast radiotherapy as good as five weeks in early breast cancer? – 10 year follow-up in the Canadian trial of hypofractionated radiation therapy. Breast Care (Basel). 2010;5:272–4.CrossRefGoogle Scholar
  31. 31.
    Smith BD, Bellon JR, Blitzblau R, Freedman G, Haffty B, Hahn C, Halberg F, Hoffman K, Hprst K, Moran J, Patton C, Perlmutter J, Warren L, Whelan T, Wright JL, Jagsi R. Radiation therapy for the whole breast: executive summary of an American Society for Radiation Oncology (ASTRO) evidence-based guideline. Pract Radiat Oncol. 2018;8:145–52.CrossRefGoogle Scholar
  32. 32.
    NCCN Guidelines Version 1.2018 Breast Cancer. www.nccn.org.
  33. 33.
    Veronesi U, Orecchia R, Maisonneuve P, Viale G, Rotmensz N, Sangalli C, et al. Intraoperative radiotherapy versus external radiotherapy for early breast cancer (ELIOT): a randomised controlled equivalence trial. Lancet Oncol. 2013;14:1269–77.CrossRefGoogle Scholar
  34. 34.
    Vaidya JS, Wenz F, Bulsara M, Saunders C, Alvarado M, Flyger HL, et al. Risk adapted targeted intraoperative radiotherapy versus whole breast radiotherapy for breast cancer: 5-year results for local control and overall survival from TARGIT-a randomised trial. Lancet. 2013;383:1719–20.CrossRefGoogle Scholar
  35. 35.
    Barry M, Ho A, Morrow M. The evolving role of partial breast irradiation in early stage breast cancer. Ann Surg Oncol. 2013;20:2534–40.CrossRefGoogle Scholar
  36. 36.
    Correa C, Harris EE, Leonardi MC, Smith BD, Taghian AG, Thompson AM, et al. Accelerated partial breast irradiation: executive summary for the update of an ASTRO evidence-based consensus statement. Pract Radiat Oncol. 2017;7:73–9.CrossRefGoogle Scholar
  37. 37.
    Polgar C, VanLimbergen E, Pötter R, Kovacs G, Polo A, Lyczek J, et al. Patient selection for accelerated partial breast irradiation after breast conserving surgery: recommendations of GEC-ESTRO breast cancer group based on clinical evidence. Radiother Oncol. 2010;94:264–73.CrossRefGoogle Scholar
  38. 38.
    Shah C, Vicini F, Wazer DE, Arthur D, Patel RR. The American Brachytherapy Society consensus statement for accelerated partial breast irradiation. Brachytherapy. 2013;12:267–77.CrossRefGoogle Scholar
  39. 39.
    Holland R, Veling SHJ, Mravunac M, Hendriks JHCL. Histologic multifocality of Tis, T1-2 breast carcinomas: implications for clinical trials of breast-conserving surgery. Cancer. 1985;56:979–90.CrossRefGoogle Scholar
  40. 40.
    Vaidya JS, Vyas JJ, Chinoy RF, Merchant N, Sharma OP, Mittra I. Multicentricity of breast cancer: whole-organ analysis and clinical implications. Br J Cancer. 1996;74:820–4.CrossRefGoogle Scholar
  41. 41.
    Faverly DRG, Hendriks JHCL, Holland R. Breast carcinomas of limited extent: frequency, radiologic-pathologic characteristics, and surgical margin requirements. Cancer. 2001;91:647–59.CrossRefGoogle Scholar
  42. 42.
    Frazier TG, Wong RWY, Rose D. Implications of accurate pathologic margins in the treatment of primary breast cancer. Arch Surg. 1989;124:37–8.CrossRefGoogle Scholar
  43. 43.
    Rosen PP, Fracchia AA, Urban JA. “Residual” mammary carcinoma following simulated partial mastectomy. Cancer. 1975;35:739–47.CrossRefGoogle Scholar
  44. 44.
    Khan A, Arthur DW, Dale RG, Haffty BG, Vicini FA. Ultra-short course of adjuvant breast radiotherapy: promised land or primrose path? Int J Radiat Oncol Biol Phys. 2012;82:499–501.CrossRefGoogle Scholar
  45. 45.
    Khan AJ, Arthur DW, Vicini FA. On the road to intraoperative radiotherapy: more proceed with caution signs. Oncology. 2013;27(2):1–3.Google Scholar
  46. 46.
    King TA, Bolton JS, Kuske RR, Fuhrman GM, Scroggins TG, Jiang XZ. Long-term results of wide-field brachytherapy as the sole method of radiation therapy after segmental mastectomy for T (is, 1,2) breast cancer. Am J Surg. 2000;180:299–304.CrossRefGoogle Scholar
  47. 47.
    Vicini FA, Kestin L, Chen P, Benitez P, Goldstein NS, Martinez A. Limited-field radiation therapy in the management of early-stage breast cancer. J Natl Cancer Inst. 2003;95:1205–10.CrossRefGoogle Scholar
  48. 48.
    Kuske RR, Winter K, Arthur DW, Bolton J, Rabinowitz R, White J, et al. Phase II trial of brachytherapy alone after lumpectomy for select breast cancer: toxicity analysis of RTOG 2006;95-17. Int J Radiat Oncol Biol Phys. 2006;65:45–51.CrossRefGoogle Scholar
  49. 49.
    Polgar C, Sulyok Z, Fodor J, Orosz Z, Major T, Mangel L, et al. Sole brachytherapy of the tumor bed after conservative surgery for T1 breast cancer: five-year results of a phase I–II study and initial findings of a randomized phase III trial. J Surg Oncol. 2002;80:121–8.CrossRefGoogle Scholar
  50. 50.
    Polgar C, Fodor J, Major T, Nemeth G, Lövey K, Orosz Z, et al. Breast-conserving treatment with partial or whole breast irradiation for low-risk invasive breast carcinoma: 5 year results of a randomized trial. Int J Radiat Oncol Biol Phys. 2007;69:694–702.CrossRefGoogle Scholar
  51. 51.
    Keisch M, Vicini F, Kuske RR, Herbert M, White J, Quiet S, et al. Initial clinical experience with the MammoSite breast brachytherapy applicator in women with early-stage breast cancer treated with breast-conserving therapy. Int J Radiat Oncol Biol Phys. 2003;55:289–93.CrossRefGoogle Scholar
  52. 52.
    Cuttino LW, Keisch M, Jenrette JM, Dragun AE, Prestige BR, Quiet CA, et al. Multi-institutional experience using the MammoSite radiation therapy system in the treatment of early-stage breast cancer: 2-year results. Int J Radiat Oncol Biol Phys. 2008;71:107–14.CrossRefGoogle Scholar
  53. 53.
    Nelson JC, Beitsch PD, Vicini FA, Quiet CA, Garcia D, Snider HC, et al. Four-year clinical update from the American Society of Breast Surgeons MammoSite brachytherapy trial. Am J Surg. 2009;198:83–91.CrossRefGoogle Scholar
  54. 54.
    Biagioli MC, Haris EER. Accelerated partial breast irradiation: potential roles following breast conserving surgery. Cancer Control. 2010;17:191–204.CrossRefGoogle Scholar
  55. 55.
    Dickler A, Patel RR, Wazer D. Breast brachytherapy devices. Expert Rev Med Devices. 2009;6:325–33.CrossRefGoogle Scholar
  56. 56.
    Kirby AM, Coles CE, Yarnold JR. Target volume definition for external beam partial breast radiotherapy: clinical, pathological and technical studies informing current approaches. Radiother Oncol. 2010;94:255–63.CrossRefGoogle Scholar
  57. 57.
    Baglan KL, Sharpe MB, Jaffray D, Frazier RC, Fayad J, Kestin LL, et al. Accelerated partial breast irradiation using 3D conformal radiation therapy (3D-CRT). Int J Radiat Oncol Biol Phys. 2003;55:302–11.CrossRefGoogle Scholar
  58. 58.
    Chen PY, Wallace M, Mitchell C. Four-year efficacy, cosmesis, and toxicity using three-dimensional conformal external beam radiation therapy to deliver accelerated partial breast irradiation. Int J Radiat Oncol Biol Phys. 2010;76:991–7.CrossRefGoogle Scholar
  59. 59.
    Orecchia R, Veronesi U. Intraoperative electrons. Semin Radiat Oncol. 2005;15:76–83.CrossRefGoogle Scholar
  60. 60.
    Azria D, Lemanski C. Intraoperative radiotherapy for breast cancer. Lancet. 2014;383(9917):578–81.CrossRefGoogle Scholar
  61. 61.
    Evans SB, Higgins SA. Intraoperative radiotherapy for breast cancer: deceptively simple? Oncology (Williston Park). 2013;27(2):122–4.Google Scholar
  62. 62.
    Ash RB, Williams VL, Wagman LD, Forouzannia A. Intraoperative radiotherapy for breast cancer: its perceived simplicity. Oncology (Williston Park). 2013;27(2):107–13.Google Scholar
  63. 63.
    Njeh CF, Saunders MW, Langton CM. Accelerated partial breast irradiation: a review of available techniques. Radiat Oncol. 2010;5:90–118.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Radiation Oncology, Medicana International HospitalIstanbulTurkey
  2. 2.Department of Radiation OncologyFlorence Nightingale HospitalIstanbulTurkey

Personalised recommendations